114 related articles for article (PubMed ID: 10987428)
21. Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine: lack of interactions.
Illi A; Sundberg S; Ojala-Karlsson P; Scheinin M; Gordin A
Eur J Clin Pharmacol; 1996; 51(3-4):273-6. PubMed ID: 9010698
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone.
Keränen T; Gordin A; Karlsson M; Korpela K; Pentikäinen PJ; Rita H; Schultz E; Seppälä L; Wikberg T
Eur J Clin Pharmacol; 1994; 46(2):151-7. PubMed ID: 8039535
[TBL] [Abstract][Full Text] [Related]
23. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.
Sohma Y; Hayashi Y; Ito T; Matsumoto H; Kimura T; Kiso Y
J Med Chem; 2003 Sep; 46(19):4124-35. PubMed ID: 12954064
[TBL] [Abstract][Full Text] [Related]
24. Identification of major urinary metabolites of the catechol-O-methyltransferase inhibitor entacapone in the dog.
Wikberg T; Ottoila P; Taskinen J
Eur J Drug Metab Pharmacokinet; 1993; 18(4):359-67. PubMed ID: 8020535
[TBL] [Abstract][Full Text] [Related]
25. Effect of the Catechol-O-Methyltransferase Inhibitors Tolcapone and Entacapone on Fatty Acid Metabolism in HepaRG Cells.
Grünig D; Felser A; Duthaler U; Bouitbir J; Krähenbühl S
Toxicol Sci; 2018 Aug; 164(2):477-488. PubMed ID: 29688484
[TBL] [Abstract][Full Text] [Related]
26. Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin.
Dingemanse J; Meyerhoff C; Schadrack J
Br J Clin Pharmacol; 2002 May; 53(5):485-91. PubMed ID: 11994054
[TBL] [Abstract][Full Text] [Related]
27. Clinical advantages of COMT inhibition with entacapone - a review.
Gordin A; Kaakkola S; Teräväinen H
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1343-63. PubMed ID: 15340869
[TBL] [Abstract][Full Text] [Related]
28. Liquid chromatographic determination of a new catechol-O-methyltransferase inhibitor, entacapone, and its Z-isomer in human plasma and urine.
Karlsson M; Wikberg T
J Pharm Biomed Anal; 1992 Aug; 10(8):593-600. PubMed ID: 1463794
[TBL] [Abstract][Full Text] [Related]
29. Synthesis, hydrolysis, and intraocular pressure lowering effects of fadolmidine prodrugs.
Niemi R; Huuskonen J; Laine K; Järvinen T
Int J Pharm; 2005 May; 295(1-2):121-7. PubMed ID: 15847997
[TBL] [Abstract][Full Text] [Related]
30. Synthesis of glabridin derivatives as tyrosinase inhibitors.
Jirawattanapong W; Saifah E; Patarapanich C
Arch Pharm Res; 2009 May; 32(5):647-54. PubMed ID: 19471877
[TBL] [Abstract][Full Text] [Related]
31. A novel prodrug strategy for beta-dicarbonyl carbon acids: syntheses and evaluation of the physicochemical characteristics of C-phosphoryloxymethyl (POM) and phosphoryloxymethyloxymethyl (POMOM) prodrug derivatives.
Dhareshwar SS; Stella VJ
J Pharm Sci; 2010 Jun; 99(6):2711-23. PubMed ID: 20020525
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).
Poewe WH; Deuschl G; Gordin A; Kultalahti ER; Leinonen M;
Acta Neurol Scand; 2002 Apr; 105(4):245-55. PubMed ID: 11939936
[TBL] [Abstract][Full Text] [Related]
33. No auxiliary, no byproduct strategy for water-soluble prodrugs of taxoids: scope and limitation of O-N intramolecular acyl and acyloxy migration reactions.
Skwarczynski M; Sohma Y; Noguchi M; Kimura M; Hayashi Y; Hamada Y; Kimura T; Kiso Y
J Med Chem; 2005 Apr; 48(7):2655-66. PubMed ID: 15801856
[TBL] [Abstract][Full Text] [Related]
34. Long-Acting Diclofenac Ester Prodrugs for Joint Injection: Kinetics, Mechanism of Degradation, and In Vitro Release From Prodrug Suspension.
Mertz N; Larsen SW; Kristensen J; Østergaard J; Larsen C
J Pharm Sci; 2016 Oct; 105(10):3079-3087. PubMed ID: 27475785
[TBL] [Abstract][Full Text] [Related]
35. Water-soluble gambogic acid PEGylated prodrugs: synthesis, characterization, physicochemical properties and in vitro hydrolysis.
Tang X; Zhang P; Ye H; Zhang C; Shen W; Ping Q
Pharmazie; 2008 Oct; 63(10):711-7. PubMed ID: 18972831
[TBL] [Abstract][Full Text] [Related]
36. Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile.
Qandil AM; Rezigue MM; Tashtoush BM
Eur J Pharm Sci; 2011 Jun; 43(3):99-108. PubMed ID: 21466853
[TBL] [Abstract][Full Text] [Related]
37. Glucuronidation of entacapone, nitecapone, tolcapone, and some other nitrocatechols by rat liver microsomes.
Lautala P; Kivimaa M; Salomies H; Elovaara E; Taskinen J
Pharm Res; 1997 Oct; 14(10):1444-8. PubMed ID: 9358559
[TBL] [Abstract][Full Text] [Related]
38. Preparation and physicochemical characterization of a novel water-soluble prodrug of carbamazepine.
Hemenway JN; Jarho P; Henri JT; Nair SK; VanderVelde D; Georg GI; Stella VJ
J Pharm Sci; 2010 Apr; 99(4):1810-25. PubMed ID: 19774656
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and in vitro evaluation of novel water-soluble prodrugs of buparvaquone.
Mäntylä A; Rautio J; Nevalainen T; Keski-Rahkonen P; Vepsälainen J; Järvinen T
Eur J Pharm Sci; 2004 Oct; 23(2):151-8. PubMed ID: 15451003
[TBL] [Abstract][Full Text] [Related]
40. Chemical stability of esters of nicotinic acid intended for pulmonary administration by liquid ventilation.
Hsu CH; Jay M; Bummer PM; Lehmler HJ
Pharm Res; 2003 Jun; 20(6):918-25. PubMed ID: 12817898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
